Coincident inhibition of EGFR signalling predominantly in basal keratinocytes leads to cutaneous adverse events. Only adverse reactions of the skin secondary to EGFRI treatment are addressed in this section. Patients usually experience mild to moderate symptoms that tend to improve during treatment, yet in some cases severe adverse events and progression of skin toxicities are reported. The typical changes seen during EGFRI treatment are:

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings